公开(公告)号：US11786478B2

公开(公告)日：2023-10-17

申请号：US17180465

申请日：2021-02-19

Applicant: SonoCore, Inc. ,  Fukuoka University

Inventor： Katsuro Tachibana

IPC: A61K9/50 ,  A61B8/06 ,  A61K49/00 ,  B01F23/20 ,  B01F31/00 ,  A61J1/14 ,  B65B3/00 ,  B65D51/00 ,  A61K49/22 ,  A61N7/00 ,  A61K47/02 ,  A61K47/12 ,  A61K47/24 ,  A61K47/26 ,  A61K47/42 ,  A61K9/127 ,  A61K9/10 ,  A61K47/28

CPC classification number: A61K9/5089 ,  A61B8/06 ,  A61J1/14 ,  A61K9/5052 ,  A61K49/00 ,  A61K49/0047 ,  A61K49/223 ,  A61N7/00 ,  B01F23/20 ,  B01F31/00 ,  B65B3/003 ,  B65D51/002 ,  A61K9/10 ,  A61K9/127 ,  A61K47/02 ,  A61K47/12 ,  A61K47/24 ,  A61K47/26 ,  A61K47/28 ,  A61K47/42 ,  A61N2007/0039

Abstract: A bubble manufacturing container of the present invention includes: a container body having an opening portion; and a rubber stopper provided on the opening portion of the container body. The rubber stopper is constituted so that the bubbles 1 of an inside of the container body are able to be taken by piercing an injection needle. It is preferred that the bubble manufacturing container has a fastening portion provided on the rubber stopper, having an opening and sealing the container body with the rubber stopper. Furthermore, it is preferred that the container body mounts a weight portion.

公开(公告)号：US11786467B2

公开(公告)日：2023-10-17

申请号：US17560019

申请日：2021-12-22

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall

IPC: A61K48/00 ,  A61K9/127 ,  A61K39/12 ,  C12N15/86 ,  A61K31/7088 ,  A61K39/00 ,  A61K39/39

CPC classification number: A61K9/127 ,  A61K9/1272 ,  A61K31/7088 ,  A61K39/00 ,  A61K39/12 ,  C12N15/86 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2710/16134 ,  C12N2760/18534 ,  C12N2770/36134

Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.

公开(公告)号：US20230322566A1

公开(公告)日：2023-10-12

申请号：US18135286

申请日：2023-04-17

Applicant: Revelation Health LLC

Inventor： Shayne K. Morris ,  Firas S. Harb ,  Warren P. Phillips ,  Daniel Pompa

IPC: C01B39/02 ,  A61P39/06 ,  A61K9/127 ,  A61K33/06

CPC classification number: C01B39/026 ,  A61P39/06 ,  A61K9/127 ,  A61K33/06

Abstract: Zeolites for extraction of heavy metals are given enhanced purification in a first method stage and further processed in a second method stage to form liquid and solid phases including swollen clinoptilolite fragments ranging from 200 to 2000 Daltons and formed as liposomes and usable to substantially reduce heavy metal ppm burdens for purposes of safe ingestion by mammals and reduction of heavy metal contaminants of gut, vascular and lymphatic systems of a mammalian host.

公开(公告)号：US20230312745A1

公开(公告)日：2023-10-05

申请号：US18206645

申请日：2023-06-07

Applicant: Ramot at Tel-Aviv University Ltd.

Inventor： Ranit KEDMI ,  Nuphar VEIGA ,  Itai BENHAR ,  Dan PEER

IPC: C07K16/42 ,  C07K16/30 ,  A61K9/127 ,  C12N15/11 ,  C07K16/28 ,  A61K47/54 ,  A61P35/00

CPC classification number: C07K16/30 ,  A61K9/127 ,  A61K47/543 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2812 ,  C07K16/2815 ,  C07K16/2845 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/4241 ,  C12N15/11 ,  C12N15/111 ,  C12N2320/32

Abstract: A lipidated secondary antibody is disclosed. Particles comprising same are also disclosed.

公开(公告)号：US11771669B2

公开(公告)日：2023-10-03

申请号：US17308692

申请日：2021-05-05

Applicant: SBG MEDICAL TECHNOLOGIES, INC.

Inventor： Michael Harvey Greenspan

IPC: A61K31/167 ,  A61K9/00 ,  A61K47/08 ,  A61K47/20 ,  A61K31/196 ,  A61K31/245 ,  A61K31/573 ,  A61K47/10 ,  A61P23/02 ,  A61K31/10 ,  A61K31/08 ,  A61K45/06 ,  A61K9/127

CPC classification number: A61K31/167 ,  A61K9/0014 ,  A61K9/127 ,  A61K31/08 ,  A61K31/10 ,  A61K31/196 ,  A61K31/245 ,  A61K31/573 ,  A61K45/06 ,  A61K47/08 ,  A61K47/10 ,  A61K47/20 ,  A61P23/02 ,  A61K31/196 ,  A61K2300/00 ,  A61K31/10 ,  A61K2300/00 ,  A61K31/08 ,  A61K2300/00 ,  A61K31/167 ,  A61K2300/00 ,  A61K31/245 ,  A61K2300/00 ,  A61K31/573 ,  A61K2300/00

Abstract: The described invention provides a topical delivery system comprising a pharmaceutical composition for application directly to a skin of a subject in need thereof comprising (a) an effective therapeutic amount of an active therapeutic agent; (b) chemical drivers comprising an amino benzoate local anesthetic, ethoxydiglycol and methylsulfonylmethane (MSM) that in combination are effective to synergistically deliver the therapeutic agent; and (c) a depot component for keeping the pharmaceutical composition in the skin. Methods for delivering an active therapeutic agent into skin, for keeping it in the skin, for reducing systemic side effects attributable to entry of the active agent into the blood stream, and a method for treating a condition, disease or disorder of skin topically also are described in accordance with the embodiments of the described invention.

公开(公告)号：US20230301912A1

公开(公告)日：2023-09-28

申请号：US18159010

申请日：2023-01-24

Applicant: The Regents of the University of California

Inventor： Annaliese Franz ,  Angel Cobo ,  Leah Thompson ,  David Coppage

IPC: A61K9/127 ,  A61K31/7105

CPC classification number: A61K9/127 ,  A61K31/7105

Abstract: This disclosure provides silyl lipid molecules in which one or more carbon-to-carbon double bonds in the lipophilic portion is substituted with a silicon atom. Guidance is provided by which the reader may make silyl lipid molecules from molecular building blocks, and then incorporate silyl lipid molecules into lipid nanoparticles (LNPs). The silyl LNPs can be used as carriers of pharmaceutical agents. Flexible steric and substitution patterns of silyl groups in the LNPs give the user a way to fine-tune physicochemical properties, achieving improved stability and clinical efficacy. This technology is useful for immunization or genetic therapy, such as the preparation and administration of RNA vaccines for protection against the virus that causes COVID-19.

公开(公告)号：US11767531B2

公开(公告)日：2023-09-26

申请号：US17747924

申请日：2022-05-18

Applicant: MPEG LA, L.L.C.

Inventor： Philipp Hadwiger ,  Hans-Peter Vornlocher ,  Jonathan Miles Brown ,  James Everett Dahlman ,  Kristin K. H. Neuman

IPC: C12N15/115 ,  C12N15/11 ,  C12N15/113 ,  A61K9/127 ,  A61K47/54 ,  A61K47/69

CPC classification number: C12N15/115 ,  A61K9/127 ,  A61K47/549 ,  A61K47/6911 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/346 ,  C12N2310/351 ,  C12N2310/3521 ,  C12N2310/3533 ,  C12N2310/51 ,  C12N2310/322 ,  C12N2310/3533 ,  C12N2310/321 ,  C12N2310/3521

Abstract: Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multi-gene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or to produce new or altered phenotypes in cells or organisms.

公开(公告)号：US11766408B2

公开(公告)日：2023-09-26

申请号：US17191975

申请日：2021-03-04

Applicant: The Board of Regents of the University of Texas System

Inventor： Qiang Cheng ,  Tuo Wei ,  Daniel J. Siegwart

IPC: A61K9/51 ,  A61K9/127 ,  A61K31/7105 ,  A61K8/55 ,  A61K31/713 ,  A61K38/46 ,  C07F9/10

CPC classification number: A61K9/5123 ,  A61K8/553 ,  A61K9/127 ,  A61K9/1271 ,  A61K9/1272 ,  A61K31/713 ,  A61K31/7105 ,  A61K38/465 ,  C07F9/10 ,  A61K9/51 ,  C12N2320/32

Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

公开(公告)号：US11759422B2

公开(公告)日：2023-09-19

申请号：US16837115

申请日：2020-04-01

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall ,  Ayush Verma

IPC: A61K9/127 ,  A61K9/00 ,  A61K39/39 ,  A61K9/10 ,  A61K39/155 ,  C12N15/88 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K9/127 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/1271 ,  A61K39/12 ,  A61K39/155 ,  A61K39/39 ,  C12N15/88 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/55555 ,  C12N2710/16134 ,  C12N2760/18534 ,  C12N2770/36143 ,  C12N2770/36171

Abstract: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass of between 1 kDa and 3 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1 kDa and 3 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

公开(公告)号：US20230285293A1

公开(公告)日：2023-09-14

申请号：US18040454

申请日：2021-08-05

Applicant: TAIWAN LIPOSOME COMPANY, LTD. ,  TLC BIOPHARMACEUTICALS, INC.

Inventor： Sheue-Fang SHIH ,  Carl Oscar BROWN

IPC: A61K9/127 ,  A61K31/661 ,  A61K9/00 ,  A61P19/02

CPC classification number: A61K9/127 ,  A61K31/661 ,  A61K9/0019 ,  A61P19/02

Abstract: Provided is a method for treating joint pain in a subject with arthritis. The method comprises administering to the subject with a determined grade of osteoarthritis an effective amount of intra-articular corticosteroid or pharmaceutically acceptable salt thereof in a pharmaceutical composition. Achieved is robustness of the efficacy response to a treatment with intra-articular corticosteroid in predetermined subgroups of the intent-to-treat population.